The Japanese company COLOPL takes a strategic stake of 12.5% in the capital of CBI for 12.5 million euros and entrusts it with exclusive rights to operate the Web 3.0 game Brilliantcrypto
07 juin 2024 04h30 HE
|
CRYPTO BLOCKCHAIN INDUSTRIES
The Japanese company COLOPL takes a strategic stake of 12.5% in the capital of CBI for 12.5 million euros and entrusts it with exclusive rights to operate the Web 3.0 game Brilliantcrypto COLOPL is...
Pacific Software Inc. Secures Strategic License Agreement with the University of California for Innovative Technology for Stimulating Collagen Production
15 mai 2024 09h00 HE
|
Pacific Software Inc.
Pacific Software Inc. partners with UCI to launch Dermatrix™, a revolutionary collagen-boosting peptide for cosmetics and wound healing.
TRUGOLF ANNOUNCES NEWLY EXPANDED AI TECHNOLOGY LICENSING AGREEMENT WITH MLSPATIAL
20 mars 2024 09h00 HE
|
TruGolf Holdings, Inc.
SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- TruGolf Holdings, Inc. (Nasdaq: TRUG) ("TruGolf”), among the leading sellers and distributors of golf simulator software and hardware, today...
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
28 févr. 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis and Sato today announced that the companies have entered into a strategic collaboration and licensing agreement for topical roflumilast in Japan.
Triple Hair Group signe une entente de licence avec Mother's Pharmaceutical pour le marché sud-coréen
17 oct. 2023 07h30 HE
|
Triple Hair Inc.
L'entente de licence accorde à Mother's Pharmaceutical les droits exclusifs de vente du médicament sur ordonnance Thérapie-07 de Triple Hair en Corée du Sud.L'entente est évaluée à 5,75 M$ US en...
Triple Hair Group Signs Licensing Agreement for South Korean Market with Mother’s Pharmaceutical
17 oct. 2023 07h30 HE
|
Triple Hair Inc.
Licensing agreement grants Mother’s Pharmaceutical exclusive rights to sell Triple Hair’s Therapy-07 prescription drug in South Korea.Agreement valued at US$5.75 million in upfront and milestone...
Crossject signe un nouvel accord de licence pour le traitement dans la crise d'épilepsie pour ZENEO® Midazolam avec AFT Pharmaceuticals pour l'Australie et la Nouvelle-Zélande
20 juil. 2023 10h55 HE
|
CROSSJECT
Communiqué de presse Crossject signe un nouvel accord de licence pour le traitement dans la crise d'épilepsie pour ZENEO® Midazolam avec AFT Pharmaceuticals pour l'Australie et la Nouvelle-Zélande ...
Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand
20 juil. 2023 10h55 HE
|
CROSSJECT
Press Release Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand Exclusive licensing, distribution and...
Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand
20 juil. 2023 01h30 HE
|
CROSSJECT
Press Release Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand Exclusive licensing, distribution and...
Crossject signe un nouvel accord de licence pour le traitement dans la crise d'épilepsie pour ZENEO® Midazolam avec AFT Pharmaceuticals pour l'Australie et la Nouvelle-Zélande
20 juil. 2023 01h30 HE
|
CROSSJECT
Communiqué de presse Crossject signe un nouvel accord de licence pour le traitement dans la crise d'épilepsie pour ZENEO® Midazolam avec AFT Pharmaceuticals pour l'Australie et la Nouvelle-Zélande ...